Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
By H. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag, H. Hurwitz, F. Innocenti, M. Mulcahy, E. O’Reilly, T. F. Wozniak and 5 more. Journal of Clinical Oncology, 2010
837 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/220b3eb9ce6cfdb74dae9eed1ea1a27308ec97f1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. (2014, background): “Although clinical trials of antiangiogenesis agents failed to show benefit in PDAC, a portion of patients treated with bevacizumab did exhibit a durable response (Kindler et al., 2010).”
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (2014, background): “Metastatic 1st line Gemcitabine ± bevacizumab CALGB 80303 [51] No improvement in PFS or OS”
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015, background): “The observed association of neutrophilia with angiogenesis suggests that this patient subset may benefit from the addition of antiangiogenic therapy, despite its lack of benefit in unstratified trials (8,23,35).”
- Recent progress in pancreatic cancer (2013, background): “The addition of cetuximab to gemcitabine, and of bevacizumab (vascular endothelial growth factor [VEGF] inhibitor) to gemcitabine both demonstrated no survival benefit and an increase in toxicities in phase 2 and 3 trials.(166,201) The newest combination regimen for patients with metastatic pancreat”